Возраст домена | 9 лет |
Дата окончания | Истек срок регистрации |
ИКС | |
Страниц в Google | 62 |
Страниц в Яндексе | 36 |
Dmoz | Нет |
Яндекс Каталог | Нет |
Alexa Traffic Rank | 5642596 |
Alexa Country | Нет данных |
История изменения показателей | Авторизация |
Идет сбор информации... Обновить
RxAbbVie
n/a
n/a
UTF-8
32.46 КБ
956
8 040 симв.
6 978 симв.
Данные предоставлены сервисом semrush
Сайт | Общие фразы | PR | тИЦ | Alexa Rank | Alexa Country | |
---|---|---|---|---|---|---|
![]() |
2 | 5 |
0 | 4999334 | ![]() |
|
![]() |
2 | n/a | 0 | 11731694 | ![]() |
|
![]() |
2 | n/a | 0 | 3677667 | ![]() | |
![]() |
1 | n/a | 0 | 5482613 | ![]() |
|
![]() |
1 | n/a | 0 | 23036357 | ![]() |
|
![]() |
1 | 6 |
10 | 2777354 | ![]() | |
![]() |
1 | n/a | 10 | 3956592 | ![]() |
|
![]() |
1 | 4 |
0 | 7947559 | ![]() |
|
![]() |
1 | 4 |
0 | 6979675 | ![]() |
|
![]() |
1 | 4 |
0 | 15097905 | ![]() |
|
Еще 40 сайтов после авторизации |
Данные предоставлены сервисом semrush
Внешние ссылки главной страницы ( 6 ) | |
fda.gov/medwatch/ | www.fda.gov/medwatch |
pparx.org/ | www.pparx.org |
abbviemedinfo.com/ | www.abbviemedinfo.com |
abbvie.com/contactus.html | Contact Us |
abbvie.com/privacy.html | Privacy policy |
abbvie.com/termsofuse.html | Terms of use |
Внутренние ссылки главной страницы ( 96 ) | |
<img> | |
/pdf/androgel_PI.pdf | AndroGel® (testosterone gel) 1% Full Prescribing Information |
/pdf/androgel_medguide.pdf | AndroGel® (testosterone gel) 1% Medication Guide |
/pdf/androgel1_62_PI.pdf | AndroGel® (testosterone gel) 1.62% Full Prescribing Information |
/pdf/androgel1_62_PI_SPA.pdf | AndroGel® (testosterone gel) 1.62% Full Prescribing Information - Spanish |
/pdf/androgel1_62_medguide.pdf | AndroGel® (testosterone gel) 1.62% Medication Guide |
/pdf/creon_PI.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information |
/pdf/creon_pi_CHI.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Chinese |
/pdf/creon_pi_KOR.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Korean |
/pdf/creon_pi_RUS.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Russian |
/pdf/creon_pi_SPA.pdf | CREON® (pancrelipase) Delayed-Release Capsules Full Prescribing Information - Spanish |
/pdf/creon_medguide.pdf | CREON® (pancrelipase) Delayed-Release Capsules Medication Guide |
/pdf/depacon.pdf | Depacon® (valproate sodium injection) |
/pdf/depakene.pdf | DEPAKENE® (valproic acid capsules and oral solution, USP) |
/pdf/depakene_medguide.pdf | DEPAKENE® (valproic acid capsules and oral solution, USP) Medication Guide |
/pdf/depakote.pdf | Depakote® (divalproex sodium) tablets |
/pdf/depakote_medguide.pdf | Depakote® (divalproex sodium) tablets Medication Guide |
/pdf/dep3.pdf | Depakote® ER (divalproex sodium extended-release tablets) |
/pdf/dep3_medguide.pdf | Depakote® ER (divalproex sodium extended-release tablets) Medication Guide |
/pdf/dep2.pdf | Depakote® Sprinkle Capsules (divalproex sodium delayed-release capsules) |
/pdf/dep2_medguide.pdf | Depakote® Sprinkle Capsules (divalproex sodium delayed-release capsules) Medication Guide |
/pdf/duopa_pi.pdf | DUOPA (carbidopa and levodopa) enteral suspension Full Prescribing Information with Medication Guide and Patient Instructions Fo... |
/pdf/duopa_SPA.pdf | DUOPA (carbidopa and levodopa) enteral suspension Full Prescribing Information with Medication Guide and Patient Instructions Fo... |
/pdf/duopa_pump_manual.pdf | DUOPA (carbidopa and levodopa) enteral suspension CADD-Legacy 1400 Pump Operator’s Manual |
/pdf/duopa_ifu_cpack.pdf.pdf | DUOPA: AbbVie Chest Pack Instructions For Use |
/pdf/duopa_ifu_cbpack.pdf.pdf | DUOPA: AbbVie Cross Body Pack Instructions For Use |
/pdf/duopa_ifu_hpack.pdf.pdf | DUOPA: AbbVie Hip Pack Instructions For Use |
/pdf/abbvie_instr_jtube_mrisupp.pdf | DUOPA: AbbVie J Tube Instructions For Use, Including MRI Safety Information Supplement |
/pdf/duopa_ifu_lvest.pdf.pdf | DUOPA: AbbVie Lightweight Vest Instructions For Use |
/pdf/abbvie_mrisupp.pdf | DUOPA: AbbVie MRI Safety Information Supplement |
/pdf/abbvie_instr_njtube.pdf | DUOPA: AbbVie NJ Tube Instructions For Use |
/pdf/abbvie_instr_pegtube.pdf | DUOPA: AbbVie PEG Tube Kit Instructions For Use |
/pdf/duopa_ifu_svest.pdf.pdf | DUOPA: AbbVie Snug Vest Instructions For Use |
/pdf/gengraf-cap.pdf | GENGRAF® Capsules (cyclosporine capsules, USP) |
/pdf/gengraf-oral.pdf | Gengraf® Oral Solution (cyclosporine oral solution, USP) |
/pdf/humira.pdf | HUMIRA® (adalimumab) Full Prescribing Information |
/htm/humira/humira_pi.html | HUMIRA® (adalimumab) Full Prescribing Information |
/pdf/humira_CHI.pdf | HUMIRA® (adalimumab) Full Prescribing Information - Chinese |
/pdf/humira_SPA.pdf | HUMIRA® (adalimumab) Full Prescribing Information - Spanish |
/pdf/humira_medguide.pdf | HUMIRA® (adalimumab) Medication Guide |
/pdf/ktab.pdf | K-TAB® (potassium chloride extended-release tablets, USP) |
/pdf/kaletracap_PI.pdf | KALETRA® (lopinavir/ritonavir) Capsules - Full Prescribing Information |
/pdf/kaletratabpi.pdf | KALETRA® (lopinavir/ritonavir) Tablets and KALETRA® (lopinavir/ritonavir) Oral Solution - Full Prescribing Information |
/pdf/kaletratab_medguide.pdf | KALETRA® (lopinavir/ritonavir) Tablets and KALETRA® (lopinavir/ritonavir) Oral Solution - Medication Guide |
/pdf/lupaneta_3_75_pi.pdf | LUPANETA PACK® (leuprolide acetate for depot suspension and norethindrone acetate tablets) 3.75 mg |
/pdf/lupaneta_11_25_pi.pdf | LUPANETA PACK® (leuprolide acetate for depot suspension and norethindrone acetate tablets) 11.25 mg |
/pdf/lupron3month11_25mg.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3 Month 11.25 mg |
/pdf/luprongyne_SPA.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3.75 mg and 3 Month 11.25 mg - Spanish |
/pdf/lupron3_75mg.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) GYN 3.75 mg and 3 Month 11.25 mg |
/pdf/lupronuro_pi.pdf | LUPRON DEPOT® (leuprolide acetate for depot suspension) URO |
/pdf/lupronpediatric.pdf | LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) |
/pdf/lupronpediatric_SPA.pdf | LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) - Spanish |
/pdf/marinol_PI.pdf | MARINOL® (dronabinol) Capsules Full Prescribing Information |
/pdf/marinol_PIL.pdf | MARINOL® (dronabinol) Capsules Patient Information |
/pdf/mavyret_pi.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Full Prescribing Information |
/pdf/mavyret_SPA.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Full Prescribing Information - Spanish |
/pdf/mavyret_PIL.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Patient Information |
/pdf/mavyret_PIL_SPA.pdf | MAVYRET™ (glecaprevir and pibrentasvir) tablets for oral use Patient Information - Spanish |
/pdf/mivacron_PI.pdf | MIVACRON® Injection (mivacurium chloride) Full Prescribing Information |
/pdf/moderiba_PI.pdf | Moderiba™ (ribavirin, USP) Tablets |
/htm/moderiba/moderiba_pi.html | Moderiba™ (ribavirin, USP) Tablets |
/pdf/niaspan.pdf | NIASPAN® (niacin extended-release tablets) [film-coated] |
/pdf/Nimbex.pdf | NIMBEX® (cisatracurium besylate) |
/pdf/nimbex_pi.pdf | NIMBEX® (cisatracurium besylate) Injection PremierProRx™ Full Prescribing Information |
/pdf/norpi2a.pdf | NORVIR® Capsules (ritonavir capsules) |
/pdf/norvirtab_pi.pdf | NORVIR® (ritonavir tablets, oral solution, and oral powder) |
/pdf/orilissa_pi.pdf | ORILISSA™ (elagolix) tablets, for oral use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide |
/pdf/orilissa_pi_SPA.pdf | ORILISSA™ (elagolix) tablets, for oral use, 150 mg and 200 mg, Full Prescribing Information with Medication Guide - Spanish |
/pdf/orilissa_medguide.pdf | ORILISSA™ (elagolix) tablets, for oral use, 150 mg and 200 mg, Medication Guide |
/pdf/survanta_pi.pdf | SURVANTA® (beractant) intratracheal suspension Full Prescribing Information |
/pdf/synthroid.pdf | SYNTHROID® (levothyroxine sodium tablets, USP) |
/htm/synthroid/synthroid_pi.html | SYNTHROID® (levothyroxine sodium tablets, USP) |
/pdf/synthroid_SPA.pdf | SYNTHROID® (levothyroxine sodium tablets, USP) - Spanish |
/pdf/tarka.pdf | TARKA® (trandolapril/verapamil HCI ER) |
/pdf/technivie_pi.pdf | TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Full Prescribing Information and Medication Guide |
/htm/technivie/technivie_pi.html | TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Full Prescribing Information and Medication Guide |
/pdf/technivie_medguide.pdf | TECHNIVIE® (ombitasvir, paritaprevir, and ritonavir tablets), for oral use Medication Guide |
/pdf/tricorpi.pdf | TRICOR® (fenofibrate) tablets |
/pdf/tridione_pi.pdf | TRIDIONE® (trimethadione) Tablets |
/pdf/trilipix_pi.pdf | TRILIPIX® (fenofibric acid) delayed-release capsules - Full Prescribing Information |
/pdf/ultanepi.pdf | ULTANE® (sevoflurane) |
/pdf/ultanenovaplus_pi.pdf | ULTANE® (sevoflurane) - NOVAPLUS™ |
/pdf/venclexta.pdf | VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information |
/htm/venclexta/venclexta_pi.html | VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information |
/pdf/venclexta_SPA.pdf | VENCLEXTA® (venetoclax tablets) for oral use Full Prescribing Information - Spanish |
/pdf/venclexta_medguide.pdf | VENCLEXTA® (venetoclax tablets) for oral use Medication Guide |
/pdf/vicodin_apap_300mg_hydrocodone_5mg-7_5mg-10mg_PI.pdf | VICODIN® (hydrocodone bitartrate and acetaminophen tablets, USP) 5 mg/300 mg; VICODIN ES® (hydrocodone bitartrate and acetaminop... |
/pdf/viekirapak_pi.pdf | VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Full Prescribing Inf... |
/viekirapak/viekirapak_pi.html | VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Full Prescribing Inf... |
/pdf/viekirapak_medguide.pdf | VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use Medication Guide |
/pdf/viekiraxr_medguide.pdf | VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Medication Guide |
/pdf/viekiraxr_pi.pdf | VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Full Prescribing Informa... |
/htm/viekiraxr/viekiraxr_pi.html | VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir, and ritonavir) extended-release tablets, for oral use Full Prescribing Informa... |
/pdf/Zemplarcappi.pdf | ZEMPLAR® (paricalcitol) Capsules |
/pdf/zemplarivpi.pdf | ZEMPLAR® (paricalcitol) Injection |
/htm/zemplariv/zemplariv_pi.html | ZEMPLAR® (paricalcitol) Injection |
Domain names in the .com and .net domains can now be registered
with many different competing registrars. Go to http://www.internic.net
for detailed information.
Domain Name: VIEKIRAHCP.COM
Registrar: MARKMONITOR INC.
Sponsoring Registrar IANA ID: 292
Whois Server: whois.markmonitor.com
Referral URL: http://www.markmonitor.com
Name Server: ABVEGDMZNS1.ABBVIE.COM
Name Server: ABVLUDMZNS1.ABBVIE.COM
Name Server: ABVSGDMZNS1.ABBVIE.COM
Status: clientDeleteProhibited https://www.icann.org/epp#clientDeleteProhibited
Status: clientTransferProhibited https://www.icann.org/epp#clientTransferProhibited
Status: clientUpdateProhibited https://www.icann.org/epp#clientUpdateProhibited
Updated Date: 06-nov-2015
Creation Date: 18-aug-2014
Expiration Date: 18-aug-2016
>>> Last update of whois database: Sat, 13 Feb 2016 09:07:58 GMT <<<
For more information on Whois status codes, please visit https://icann.org/epp
NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.
TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.
The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.
Domain Name: viekirahcp.com
Registry Domain ID: 1871596953_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.markmonitor.com
Registrar URL: http://www.markmonitor.com
Updated Date: 2015-11-06T13:11:38-0800
Creation Date: 2014-08-18T08:29:05-0700
Registrar Registration Expiration Date: 2016-08-18T08:29:05-0700
Registrar: MarkMonitor, Inc.
Registrar IANA ID: 292
Registrar Abuse Contact Email: abusecomplaints@markmonitor.com
Registrar Abuse Contact Phone: +1.2083895740
Domain Status: clientUpdateProhibited (https://www.icann.org/epp#clientUpdateProhibited)
Domain Status: clientTransferProhibited (https://www.icann.org/epp#clientTransferProhibited)
Domain Status: clientDeleteProhibited (https://www.icann.org/epp#clientDeleteProhibited)
Registry Registrant ID:
Registrant Name: Domain Administrator
Registrant Organization: AbbVie Inc.
Registrant Street: 1 North Waukegan Road,
Registrant City: North Chicago
Registrant State/Province: IL
Registrant Postal Code: 60064
Registrant Country: US
Registrant Phone: +1.8479388258
Registrant Phone Ext:
Registrant Fax: +1.8479370019
Registrant Fax Ext:
Registrant Email: internetnameregistrar@abbvie.com
Registry Admin ID:
Admin Name: Domain Administrator
Admin Organization: AbbVie Inc.
Admin Street: 1 North Waukegan Road,
Admin City: North Chicago
Admin State/Province: IL
Admin Postal Code: 60064
Admin Country: US
Admin Phone: +1.8479388258
Admin Phone Ext:
Admin Fax: +1.8479370019
Admin Fax Ext:
Admin Email: internetnameregistrar@abbvie.com
Registry Tech ID:
Tech Name: Domain Administrator
Tech Organization: AbbVie Inc.
Tech Street: 1 North Waukegan Road,
Tech City: North Chicago
Tech State/Province: IL
Tech Postal Code: 60064
Tech Country: US
Tech Phone: +1.8479388258
Tech Phone Ext:
Tech Fax: +1.8479370019
Tech Fax Ext:
Tech Email: internetnameregistrar@abbvie.com
Name Server: abvludmzns1.abbvie.com
Name Server: abvsgdmzns1.abbvie.com
Name Server: abvegdmzns1.abbvie.com
>>> Last update of WHOIS database: 2016-02-13T01:08:12-0800 <<<
The Data in MarkMonitor.com's WHOIS database is provided by MarkMonitor.com for
information purposes, and to assist persons in obtaining information about or
related to a domain name registration record. MarkMonitor.com does not guarantee
its accuracy. By submitting a WHOIS query, you agree that you will use this Data
only for lawful purposes and that, under no circumstances will you use this Data to:
(1) allow, enable, or otherwise support the transmission of mass unsolicited,
commercial advertising or solicitations via e-mail (spam); or
(2) enable high volume, automated, electronic processes that apply to
MarkMonitor.com (or its systems).
MarkMonitor.com reserves the right to modify these terms at any time.
By submitting this query, you agree to abide by this policy.
MarkMonitor is the Global Leader in Online Brand Protection.
MarkMonitor Domain Management(TM)
MarkMonitor Brand Protection(TM)
MarkMonitor AntiPiracy(TM)
MarkMonitor AntiFraud(TM)
Professional and Managed Services
Visit MarkMonitor at http://www.markmonitor.com
Contact us at +1.8007459229
In Europe, at +44.02032062220
For more information on Whois status codes, please visit
https://www.icann.org/resources/pages/epp-status-codes-2014-06-16-en
США - Ашберн - 64.207.154.158
Media Temple
Media Temple
HTTP/1.1 200 OK
Accept-Ranges: bytes
Cache-control: no-cache="set-cookie"
Content-Type: text/html; charset=UTF-8
Date: Sat, 13 Apr 2019 02:11:34 GMT
ETag: W/"81db-5865ff045796b"
Last-Modified: Sat, 13 Apr 2019 02:11:34 GMT
Server: Apache
Set-Cookie: AWSELB=55E1F9710AF5F165CF739C7EAD57633D43724D49E25CA2932B4129431ECE6EFB1E70BEBCB057B0FB475B0E07AA70562B689A64D17D7B69E03F2A473A39EC32A32BE7B1591A;PATH=/;MAX-AGE=900
Vary: Accept-Encoding
Content-Length: 33243
Connection: Close
Кнопка для анализа сайта в один клик, для установки перетащите ссылку на "Панель закладок"